NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Hester Biosciences FY26 Consolidated Revenue Hits ₹332.6 Cr; PAT Surges to ₹57.5 Cr
Hester Biosciences reported a strong financial performance for FY 2025-26, with consolidated revenue reaching ₹332.60 crore. The company witnessed a significant recovery in profitability, with consolidated Profit After Tax (PAT) jumping to ₹57.48 crore from ₹21.17 crore in the previous fiscal year. Hester maintains a dominant 35% market share in the Indian poultry vaccine market and is the world's largest supplier of the PPR vaccine. The company is strategically diversifying, with the Animal Healthcare division now contributing 38% to consolidated revenue.
முக்கிய அம்சங்கள்
Consolidated revenue grew to ₹332.60 crore in FY26 compared to ₹311.10 crore in FY25.Consolidated PAT surged to ₹57.48 crore, a substantial increase from ₹21.17 crore in the prior year.Maintains a 35% market share in the Indian poultry vaccine segment as the second-largest manufacturer.Annual manufacturing capacity stands at 8.6 billion doses in India, 1.24 billion in Nepal, and 1.5 billion in Africa.Animal Healthcare division's revenue contribution rose to 38% on a consolidated basis, up from 29% on a standalone basis.
👀 கவனிக்க வேண்டியவை
Investors should view the sharp turnaround in profitability and margin expansion as a positive sign of operational efficiency. The company's leading position in global vaccine banks and expansion into the Petcare segment provide long-term growth visibility.
Hester Biosciences: Promoters Ravin and Bela Gandhi Seek Reclassification of 9.45% Stake to Public
Hester Biosciences has received formal requests from two members of its promoter group, Mr. Ravin Gandhi and Ms. Bela Gandhi, to be reclassified as public shareholders. Mr. Ravin Gandhi holds a 4.74% stake (403,320 shares) and recently resigned from the Board, while Ms. Bela Gandhi holds a 4.71% stake (400,635 shares). Together, they represent 9.45% of the company's voting rights and have declared they no longer exercise management control or hold special rights. The company is now initiating the necessary regulatory steps under SEBI guidelines to process these requests.
முக்கிய அம்சங்கள்
Mr. Ravin Gandhi (4.74% stake) and Ms. Bela Gandhi (4.71% stake) have applied for reclassification from 'Promoter' to 'Public' category.The combined shareholding involved in the reclassification request totals 803,955 equity shares or 9.45% of the company.Mr. Ravin Gandhi resigned from the Board of Directors effective May 12, 2026, to facilitate this transition.Ms. Bela Gandhi confirmed she has had no involvement in company management for the last 12 years.The reclassification is subject to approval from the company's shareholders and the stock exchanges under SEBI Regulation 31A.
👀 கவனிக்க வேண்டியவை
Investors should view this as a standard regulatory restructuring of shareholding; however, monitor if this leads to any future secondary market sales by these individuals once they are classified as public. The move does not impact the company's day-to-day operations or business fundamentals.
Hester Biosciences Q4 PAT Surges 174% to INR 26.38 Cr; Declares INR 11 Dividend
Hester Biosciences reported a robust performance for Q4 FY26, with standalone revenue growing 22% YoY to INR 93.71 crore. Net profit for the quarter saw a significant jump of 174% YoY to INR 26.38 crore, bolstered by an exceptional gain of INR 6.99 crore from a subsidiary sale. The Board has recommended a healthy dividend of INR 11 per share (110% of face value). The Poultry Healthcare segment continues to be the primary growth engine, while the company also confirmed the re-appointment of Ms. Priya Gandhi as Executive Director.
முக்கிய அம்சங்கள்
Standalone Q4 FY26 PAT rose to INR 263.84 million from INR 96.35 million in the previous year's quarter.Full-year FY26 PAT increased by 63.6% to INR 521.00 million compared to INR 318.42 million in FY25.Recommended a final dividend of INR 11 per equity share (110%) for the financial year 2025-26.Poultry Healthcare segment revenue grew 41% YoY in Q4 to INR 650.72 million.Recorded an exceptional gain of INR 69.96 million in Q4 FY26 from the sale of investment in a subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin improvement and the strong recovery in the poultry segment. The healthy dividend payout and profit growth make this a positive update for long-term shareholders.
Hester Biosciences Recommends ₹11 Dividend; FY26 PAT Surges 64% to ₹521 Million
Hester Biosciences has recommended a final dividend of ₹11 per share for FY26, representing a 110% payout on face value. The company reported a strong financial performance with annual standalone Profit After Tax (PAT) rising 64% to ₹521 million, driven by significant growth in the Poultry Healthcare segment. Quarterly performance was particularly robust, with Q4 PAT jumping to ₹263.84 million from ₹96.35 million in the previous year. Additionally, the board approved the re-appointment of Ms. Priya Gandhi as Executive Director for a three-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹11 per equity share (110%) for the financial year 2025-26.Standalone annual Profit After Tax (PAT) increased by 63.6% YoY to ₹521 million.Q4 FY26 Revenue from operations grew 22% YoY to ₹937.13 million compared to ₹766.72 million.Poultry Healthcare segment revenue grew to ₹2,061.31 million in FY26 from ₹1,665.83 million in FY25.Earnings Per Share (EPS) improved significantly to ₹61.24 for FY26 compared to ₹37.43 in FY25.
👀 கவனிக்க வேண்டியவை
Investors should consider the strong bottom-line growth and healthy dividend payout as a sign of improved operational efficiency. The significant jump in Q4 margins and Poultry segment growth makes this a positive development for long-term holders.
Ester Industries Q4 PAT Surges 301% to ₹7.9 Cr; Proposes ₹0.25 Dividend
Ester Industries reported a strong recovery in Q4 FY26 with consolidated revenue growing 7.2% YoY to ₹345.1 crore and PAT surging 301% to ₹7.9 crore. While the full year FY26 ended in a consolidated loss of ₹27.5 crore, the company saw significant margin expansion in the final quarter due to anti-dumping duties on BOPET films and favorable regulatory shifts. The Specialty Polymers and rPET segments showed robust growth, with rPET revenue increasing 3.6x YoY. Additionally, the company successfully raised ₹165.25 crore through share warrants, strengthening its capital position.
முக்கிய அம்சங்கள்
Consolidated Q4 PAT jumped 301% YoY to ₹7.9 crore, with EBITDA margins improving to 12.6%.Full-year FY26 consolidated revenue grew 7.2% to ₹1,392.7 crore, despite a net loss of ₹27.5 crore for the year.rPET segment revenue grew by 3.6x YoY to ₹59.3 crore, supported by Plastic Waste Management Rules.Successfully secured ₹165.25 crore against a ₹175 crore share warrant issue from promoters and investors.Board of Directors proposed a dividend of ₹0.25 per share for the financial year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should focus on the sharp Q4 turnaround and the growth in high-margin specialty segments as indicators of a recovery trend. The successful capital infusion and anti-dumping protections provide a better outlook for FY27.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Ester Industries Recommends ₹0.25 Dividend and Appoints New Internal Auditors
Ester Industries has announced its audited financial results for the fiscal year ended March 31, 2026, reporting a consolidated net loss for the period. Despite the loss, the Board of Directors has recommended a final dividend of ₹0.25 per equity share of face value ₹5. The company also strengthened its governance by appointing Nangia Global Advisors LLP as Internal Auditors and re-appointing R J Goel & Co. as Cost Auditors for FY 2026-27. The statutory auditors, Walker Chandiok & Co LLP, issued an unmodified opinion on the standalone financial results.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹0.25 per equity share (5% of face value) for FY 2025-26.Appointed M/s. Nangia Global Advisors LLP as Internal Auditors for the financial year 2026-27.Re-appointed M/s. R J Goel & Co. as Cost Auditors for the upcoming fiscal year.Reported a consolidated net loss for the year ended March 31, 2026, as per the auditor's report.Statutory auditors provided an unmodified opinion on the standalone financial results for the year.
👀 கவனிக்க வேண்டியவை
Investors should analyze the full financial statements to identify the drivers behind the consolidated net loss and evaluate if the dividend payout is sustainable. Monitor the company's operational performance in the coming quarters to see if the new internal audit controls improve cost management.
Ester Industries Recommends Final Dividend of Rs 0.25 per Share for FY26
The Board of Ester Industries has recommended a final dividend of Rs 0.25 per equity share for the financial year ended March 31, 2026. This dividend is subject to shareholder approval at the upcoming Annual General Meeting. While the company is maintaining a payout, the statutory auditor's report highlights that the group incurred a consolidated net loss for the fiscal year. Additionally, the company has appointed Nangia Global Advisors LLP as new internal auditors for FY 2026-27.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 0.25 per equity share of face value Rs 5 each.Auditor's report indicates a consolidated net loss for the financial year ended March 31, 2026.Nangia Global Advisors LLP appointed as Internal Auditors for the 2026-27 financial year.M/s. R J Goel & Co. re-appointed as Cost Auditors for the 2026-27 financial year.
👀 கவனிக்க வேண்டியவை
Investors should weigh the dividend against the reported consolidated net loss for the year. It is advisable to review the detailed financial results to understand the drivers behind the loss before making further investment decisions.
Ester Industries Allots 67.08 Lakh Equity Shares on Warrant Conversion at Rs 158/Share
Ester Industries has approved the allotment of 67,08,851 equity shares following the conversion of warrants originally issued in November 2024. The shares were issued at a price of Rs 158 each, which includes a premium of Rs 153 per share. Notably, the promoter, Mr. Arvind Singhania, subscribed to 37,97,468 shares, while the remaining 29,11,383 shares were allotted to public category entities. This conversion has increased the company's total paid-up equity share capital to approximately Rs 52.15 crore.
முக்கிய அம்சங்கள்
Allotment of 67,08,851 equity shares of face value Rs 5 each upon warrant conversionConversion price set at Rs 158 per share, including a premium of Rs 153Promoter Arvind Singhania acquired 37,97,468 shares, representing over 56% of the allotmentTotal paid-up capital increased to Rs 52,14,75,210 comprising 10,42,95,042 sharesSix public category entities, including K&K Ventures and various foundations, received 29,11,383 shares
👀 கவனிக்க வேண்டியவை
Investors should view the promoter's significant participation in the warrant conversion as a positive sign of confidence in the company's future. While there is a minor equity dilution, the capital infusion at Rs 158 per share provides a supportive valuation benchmark.
Ester Industries Proposes Leadership Re-designation and Remuneration Hike to ₹3 Crore
Ester Industries has issued a postal ballot notice seeking shareholder approval for significant leadership changes and compensation revisions. Mr. Arvind Singhania is set to transition from Managing Director and CEO to a Non-Executive Chairman role effective March 26, 2026. Additionally, the company is proposing a salary hike for Whole-time Director Mr. Ayush Vardhan Singhania, with a new annual remuneration range of ₹2.70 Crores to ₹3.00 Crores. Shareholders can cast their votes via e-voting between April 24 and May 23, 2026.
முக்கிய அம்சங்கள்
Mr. Arvind Singhania to transition from MD & CEO to Non-Executive Chairman effective March 26, 2026Proposed remuneration for Whole-time Director Mr. Ayush Vardhan Singhania increased to ₹2.70 Cr - ₹3.00 Cr per annumRemote e-voting period scheduled from April 24, 2026, to May 23, 2026Postal ballot results to be declared on or before May 26, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the leadership transition as the current CEO moves to a non-executive role, potentially signaling a succession plan. Evaluate whether the proposed remuneration increase for the Whole-time Director is justified by the company's recent financial performance.
Ester Industries Appoints Vaibhav Jha as CEO; Arvind Singhania Transitions to Chairman
Ester Industries has announced a major leadership transition with Mr. Vaibhav Jha appointed as the new Chief Executive Officer effective March 27, 2026. Mr. Jha, an MBA from IIT Bombay, brings over 21 years of experience from top-tier organizations including Reliance Industries and Infosys. Concurrently, co-founder Mr. Arvind Singhania will step down from his executive role as MD and CEO to become the Non-Executive Chairman after 40 years of service. This move represents a significant shift towards professional management while maintaining founder oversight at the board level.
முக்கிய அம்சங்கள்
Mr. Vaibhav Jha appointed as CEO effective March 27, 2026, with 21+ years of multi-industry experience.Co-founder Mr. Arvind Singhania transitions to Non-Executive Chairman after leading the company since 1985.New CEO Vaibhav Jha holds an MBA from IIT Bombay and previously worked at Reliance Industries and Infosys.The leadership change is subject to approval from the company's members via a postal ballot.Mr. Ayush Vardhan Singhania continues as Whole Time Director, maintaining family representation in management.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's operational performance and strategic shifts under the new professional CEO over the next few quarters. The transition from a founder-led to a professionally-managed structure is generally positive for long-term governance but requires a 'watch' approach during the initial phase.
Ester Industries Shareholders Approve MD Re-appointment and Key Related Party Transactions
Ester Industries Limited has announced the successful passage of five resolutions via postal ballot, ensuring leadership continuity and regulatory compliance for related party transactions. Shareholders approved the re-appointment of Mr. Arvind Singhania as Managing Director with 99.44% of the votes and Mr. Pradeep Kumar Rustagi as Whole-time Director with 99.98% support. Furthermore, material related party transactions with Ester Loop Infinite Technologies, Wilemina Finance Corporation, and Mr. Arvind Singhania were all approved with majorities exceeding 99.4%. These results reflect strong shareholder confidence in the company's current leadership and governance.
முக்கிய அம்சங்கள்
Special Resolution for re-appointment of Mr. Arvind Singhania as MD passed with 99.44% favor.Special Resolution for re-appointment of Mr. Pradeep Kumar Rustagi as WTD passed with 99.98% favor.Three Ordinary Resolutions for material Related Party Transactions approved with over 99.4% majority each.Total of 8,206,120 votes were polled for the MD re-appointment resolution (excluding interested promoters).The voting period concluded on March 21, 2026, with results declared on March 24, 2026.
👀 கவனிக்க வேண்டியவை
The high approval ratings for management re-appointments suggest stable leadership, which is a positive sign for long-term holders. Investors should continue to monitor the nature of the approved related party transactions in future financial disclosures.
Hester Biosciences Credit Rating Downgraded to CARE BBB; Stable by CARE Ratings
CARE Ratings has downgraded Hester Biosciences' long-term bank facilities from 'CARE BBB+; Stable' to 'CARE BBB; Stable' and short-term ratings from 'A2' to 'A3+'. The downgrade follows a review of the company's FY25 audited and 9MFY26 unaudited financial performance. Management has labeled this downgrade as 'transitional,' pointing towards recent improvements in operating margins, ROCE, and debt coverage ratios post-September 2025. The company maintains adequate liquidity for its debt obligations and has recently secured a manufacturing license for the Avian Influenza H9N2 vaccine.
முக்கிய அம்சங்கள்
Long-term bank facilities downgraded to CARE BBB; Stable from CARE BBB+; StableShort-term bank facilities downgraded to CARE A3+ from CARE A2Total bank facilities rated by CARE Ratings amount to ₹131.47 croreManagement reports improved debt coverage indicators in H1FY26 despite the rating actionCompany holds 75% global market share in PPR vaccine and 35% Indian market share in poultry vaccines
👀 கவனிக்க வேண்டியவை
Investors should exercise caution due to the credit downgrade, which may increase future borrowing costs. Monitor upcoming quarterly results to see if the management's claim of a 'transitional' phase reflects in actual bottom-line improvement and debt reduction.
Hester Biosciences to Divest 43.81% Stake in Texas Lifesciences for INR 92 Million
Hester Biosciences has announced the divestment of a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for a total consideration of INR 92 million. Following the sale to Ticop Life Private Limited, Hester will retain an 11% stake, and TLPL will cease to be a subsidiary. TLPL reported a turnover of INR 285.89 million in FY 2024-25, though over 97% of its sales were internal to Hester. This move allows Hester to unlock capital while maintaining a strategic business relationship with the entity.
முக்கிய அம்சங்கள்
Divesting 43.81% stake out of 54.81% total holding in Texas Lifesciences Private Limited.Total aggregate consideration for the sale is INR 92 million.TLPL's FY 2024-25 turnover was INR 285.89 million with a net worth of INR 134.17 million.Hester will maintain an 11% equity stake and continue business operations with TLPL.The transaction is expected to be completed within three months from March 5, 2026.
👀 கவனிக்க வேண்டியவை
Investors should watch for the impact on consolidated margins since TLPL's internal sales were previously eliminated, and monitor the utilization of the INR 92 million proceeds.
Hester Biosciences Re-appoints Rajiv Gandhi as CEO & MD for 3 Years with 99.54% Approval
Hester Biosciences has announced the successful re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director for a three-year term effective from April 1, 2026. The special resolution was passed via a postal ballot process with an overwhelming 99.54% of valid votes cast in favor. While the promoter group showed 100% support, a significant majority of the small institutional voting block (99.24%) voted against the resolution. This move ensures leadership continuity for the company through March 2029.
முக்கிய அம்சங்கள்
Special resolution for re-appointment of Rajiv Gandhi as CEO & MD passed with 99.54% majority.The new term is effective for three years from April 1, 2026, to March 31, 2029.Total valid votes cast represented 4,075,085 shares, with 4,056,419 votes in favor.Promoter group cast 3,451,082 votes, showing 100% internal support for the leadership.Public institutional holders showed 99.24% dissent, though this represented only 18,570 shares.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the leadership continuity which supports long-term strategic stability. No immediate action is required as the current management remains at the helm.
Ester Industries Seeks Approval for ₹1,463 Cr RPT and Leadership Re-appointments
Ester Industries has issued a postal ballot notice to re-appoint its Chairman & CEO, Arvind Singhania, and Executive Director, Pradeep Kumar Rustagi, for three-year terms starting April 2026. A major highlight is the request for shareholder approval for material related party transactions (RPT) worth up to ₹1,463 crore with its associate company, Ester Loop Infinite Technologies, for FY 2026-27. Additionally, the company seeks a ₹380 crore limit for corporate guarantees from its promoter entity, Wilemina Finance Corporation. These resolutions aim to ensure leadership continuity and facilitate large-scale operational funding and trade.
முக்கிய அம்சங்கள்
Re-appointment of Arvind Singhania as MD (Chairman & CEO) for 3 years effective April 1, 2026Proposed material Related Party Transactions with associate ELITe totaling up to ₹1,463 crore for FY27Approval sought for corporate guarantees up to ₹380 crore from holding company Wilemina Finance CorporationRe-appointment of Pradeep Kumar Rustagi as Whole-Time Director for a further 3-year termPostal ballot results to be declared on or before March 23, 2026
👀 கவனிக்க வேண்டியவை
Investors should review the explanatory statement for the ₹1,463 crore RPT to ensure terms are at arm's length and beneficial for the company's margins. Leadership stability is positive, but the scale of transactions with the associate company warrants close monitoring.
Ester Industries Q3 FY26: EBITDA Drops 67.7% to INR 21 Cr Amid Global Headwinds
Ester Industries reported a subdued Q3 FY26 with consolidated revenue declining 2.1% YoY to INR 343.5 crores and EBITDA falling sharply by 67.7% to INR 21 crores. The performance was hit by Chinese dumping of BOPET films, high US trade tariffs, and one-time labor code implementation costs of INR 2.68 crores. However, the Specialty Polymers segment remained a bright spot, posting a 72.9% revenue growth and a 61.8% increase in EBIT. Management anticipates a recovery by mid-March 2026 following a US-India trade deal expected to reduce tariffs from 50% to 18%.
முக்கிய அம்சங்கள்
Consolidated EBITDA margin compressed to 6.1% from 18.6% YoY due to aggressive price competition and forex losses.Specialty Polymers segment saw robust volume growth of 46.4% and revenue growth of 72.9% in Q3 FY26.US-India trade deal expected by mid-March 2026 to reduce BOPET film tariffs from 50% to 18%, boosting future margins.The 'Elite' chemical recycling JV project is progressing with land acquisition expected by April-May 2026.Polyester film segment revenue declined 8.9% YoY to INR 287.7 crores due to lower realizations and maintenance shutdowns.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the formal signing of the US-India trade deal in March 2026, which is the primary catalyst for a turnaround in the film business. While current earnings are under pressure, the strong growth in Specialty Polymers and the upcoming recycling project provide a long-term positive outlook.
Ester Industries reported its Q3 FY26 performance, where Polyester Films accounted for 85% of revenue and Specialty Polymers 15%. The company is navigating margin pressures in the BOPET segment due to US trade tariffs and predatory pricing from China, leading to a revised value-added product target of 25%. A key strategic highlight is the $180 million ELITe joint venture with Loop Industries, which has secured a multi-year offtake agreement with Nike for sustainable materials. Commercial operations for this JV are expected to commence in H2 CY 2027.
முக்கிய அம்சங்கள்
ELITe JV with Loop Industries involves a $180 million investment for chemical recycling with H2 CY 2027 start dateSecured a multi-year offtake agreement with Nike as an anchor customer for the new recycling facilityValue-added product share target for Q4 FY26 revised to 25% from 30% due to US trade tariff impactsTotal installed capacity stands at 108 KTPA for Polyester Films and 30 KTPA for Specialty PolymersPolyester Film segment margins are currently under pressure from Chinese imports and global trade dynamics
👀 கவனிக்க வேண்டியவை
Investors should focus on the execution of the ELITe JV and the recovery of margins in the Specialty Polymers segment. While the Nike deal is a significant long-term positive, short-term performance will be dictated by the company's ability to mitigate US tariff impacts and Chinese competition.
Ester Industries Q3 FY26: Consolidated Net Loss of ₹12.4 Cr Amid BOPET Margin Pressure
Ester Industries reported a challenging Q3 FY26 with consolidated revenue declining 2.1% to ₹343.5 crore and a net loss of ₹12.4 crore, down from a profit of ₹24.8 crore in the previous year. The performance was severely impacted by high US trade tariffs (50%) and predatory pricing from Chinese BOPET film imports, causing EBITDA to crash 67.7% to ₹21.0 crore. However, the Specialty Polymers segment remained a bright spot, with volume growth of 46.4% and EBIT rising 61.8% to ₹16 crore. Management is optimistic about a recovery following a proposed US-India trade deal in March 2026 which could slash tariffs to 18%.
முக்கிய அம்சங்கள்
Consolidated EBITDA margins contracted sharply from 18.5% to 6.1% due to external trade pressures.Specialty Polymer segment EBIT grew 61.8% YoY to ₹16 crore, driven by a 46.4% increase in sales volume.rPET revenue surged approximately 4x YoY to ₹15.2 crore on the back of 286.7% volume growth.Currency volatility and Rupee depreciation led to significant mark-to-market losses during the nine-month period.US-India trade deal expected by mid-March 2026 is projected to reduce import tariffs from 50% to 18%.
👀 கவனிக்க வேண்டியவை
Investors should closely watch the formal signing of the US-India trade deal in March 2026 and the DGTR anti-dumping investigation results as primary catalysts for margin recovery. While the current earnings are weak, the strong growth in Specialty Polymers and rPET segments indicates a positive shift in the product mix.
Ester Industries Re-appoints CEO Arvind Singhania and ED Pradeep Rustagi for 3-Year Terms
Ester Industries has approved the re-appointment of co-founder Mr. Arvind Singhania as Managing Director and CEO for a three-year term effective April 1, 2026. Mr. Pradeep Kumar Rustagi has also been re-appointed as Whole-time Director for the same period, ensuring leadership continuity through March 2029. The board concurrently approved the un-audited financial results for the quarter ended December 31, 2025. Additionally, the company is seeking shareholder approval for material related party transactions with Ester Loop Infinite Technologies for FY 2026-27.
முக்கிய அம்சங்கள்
Re-appointment of Mr. Arvind Singhania as MD & CEO for a 3-year term starting April 1, 2026.Re-appointment of Mr. Pradeep Kumar Rustagi as Whole-time Director for a 3-year term starting April 1, 2026.Approval of un-audited standalone and consolidated financial results for Q3 FY26.Proposed material related party transactions with Ester Loop Infinite Technologies Private Limited for FY 26-27.Leadership continuity maintained with executives possessing over 38 and 40 years of experience respectively.
👀 கவனிக்க வேண்டியவை
The re-appointments signal management stability, which is generally positive for long-term strategy execution. Investors should monitor the specific Q3 financial performance and the details of the proposed related party transactions.
Ester Industries Re-appoints Top Leadership and Approves Material Related Party Transactions
The Board of Ester Industries has approved the re-appointment of Mr. Arvind Singhania as Managing Director (CEO) and Mr. Pradeep Kumar Rustagi as Whole-time Director for three-year terms effective April 1, 2026. The company also reviewed its financial results for the quarter ended December 31, 2025, though specific financial figures were not included in the primary announcement text. Additionally, the board has proposed material related party transactions with Ester Loop Infinite Technologies for FY 2026-27, which will require shareholder approval via postal ballot.
முக்கிய அம்சங்கள்
Re-appointment of Mr. Arvind Singhania as Executive Chairman & CEO for a 3-year term until March 2029.Re-appointment of Mr. Pradeep Kumar Rustagi as Executive Director-Corporate Affairs for a 3-year term.Approval of Material Related Party Transactions with Ester Loop Infinite Technologies Private Limited for FY 2026-27.Board meeting concluded on February 6, 2026, approving un-audited standalone and consolidated financial results.Shareholder approval to be sought via Postal Ballot for leadership re-appointments and related party transactions.
👀 கவனிக்க வேண்டியவை
Investors should view the leadership re-appointments as a sign of operational continuity. However, it is advised to review the specific details of the material related party transactions once the postal ballot notice is released to ensure governance standards.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
